科伦药业股价上涨1.18% 子公司入选中国科技50强

Core Insights - Kelong Pharmaceutical's latest stock price is 37.76 yuan, up 1.18% from the previous trading day, with a trading volume of 5.22 billion yuan [1] Company Overview - Kelong Pharmaceutical primarily engages in the research, production, and sales of large-volume injectables, small-volume injectables, tablets, and capsules [1] - The company's subsidiary, Kelong Botai Biotech, focuses on the development of innovative biopharmaceuticals and small molecule drugs, with its core product being the first fully approved original TROP2ADC drug in China, Lukanasatuzumab [1] Recent Developments - Kelong Botai Biotech has been included in the 2025 Fortune China Technology 50 list, representing a leading company in the innovative drug sector [1] - The company is working to position China's ADC drugs among the global top tier [1] Financial Performance - On the day of the report, Kelong Pharmaceutical experienced a net inflow of 29.36 million yuan in main funds, although the overall trend over the past five days shows a net outflow of 154 million yuan [1]